Control of the cell cycle and apoptosis

European Journal of Cancer

Volumn 35, Issue 14, 1999, Pages 1886-1894

  Lundberg, A S ^a   Weinberg, R A ^a  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; CYCLIN E; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PROTEIN P53;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; GENOME; HUMAN; MUTATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SENESCENCE; TUMOR SUPPRESSOR GENE;

EID: 0033377979     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00292-0     Document Type: Article

References (85)

1. Evans T., Rosenthal E.T., Youngblom J., Distel D., Hunt T. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is. Cell. 33:1983;389-396.
2. Hunter T., Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 79:1994;573-582.
3. Pardee A.B. A restriction point for control of normal animal cell proliferation. Proc. Natl. Acad. Sci. USA. 71:1974;1286-1290.
4. Elledge S.J. Cell cycle checkpoints: preventing an identity crisis. Science. 274:1996;1664-1672.
5. Nurse P. Checkpoint pathways come of age. Cell. 91:1997;865-867.
6. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell. 81:1995;323-330.
7. Lundberg A.S., Weinberg R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell Biol. 18:1998;753-761.
8. Nevins J.R. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Different. 9:1998;585-593.
9. Brehm A., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature. 391:1998;597-601.
10. Magnaghi-Jaulin L., Groisman R., Naguibneva I.et al. Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature. 391:1998;601-605.
11. Luo R.X., Postigo A.A., Dean D.C. Rb interacts with histone deacetylase to repress transcription. Cell. 92:1998;463-473.
12. Matsushime H., Roussel M.F., Ashmun R.A., Sherr C.J. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell. 65:1991;701-713.
13. Liu J.J., Chao J.R., Jiang M.C., Ng S.Y., Yen J.J., Yang-Yen H.F. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol. Cell Biol. 15:1995;3654-3663.
14. Filmus J., Robles A.I., Shi W., Wong M.J., Colombo L.L., Conti C.J. Induction of cyclin D1 overexpression by activated ras. Oncogene. 9:1994;3627-3633.
15. Leone G., De Gregori J., Sears R., Jakoi L., Nevins J.R. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature. 387:1997;422-426.
16. Mittnacht S., Paterson H., Olson M.F., Marshall C.J. Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr. Biol. 7:1997;219-221.
17. Peeper D.S., Upton T.M., Ladha M.H.et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein [published erratum appears in Nature 1997 Apr 3; 386(6624):521]. Nature. 386:1997;177-181.
18. Sicinski P., Donaher J.L., Geng Y.et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature. 384:1996;470-474.
19. Resnitzky D., Gossen M., Bujard H., Reed S.I. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell Biol. 14:1994;1669-1679.
20. Polyak K., Lee M.H., Erdjument-Bromage H.et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 78:1994;59-66.
21. INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 371:1994;257-261.
22. Planas-Silva M.D., Weinberg R.A. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol. Cell Biol. 17:1997;4059-4069.
23. Galaktionov K., Chen X., Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature. 382:1996;511-517.
24. Fleming T.P., Matsui T., Molloy C.J., Robbins K.C., Aaronson S.A. Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors. Proc. Natl. Acad. Sci. USA. 86:1989;8063-8067.
25. Lonardo F., Di Marco E., King C.R.et al. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol. 2:1990;992-1003.
26. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
27. Sherr C.J. Mammalian G1 cyclins. Cell. 73:1993;1059-1065.
28. Weinberg R.A. Tumor suppressor genes. Science. 254:1991;1138-1146.
29. Munger K. The molecular biology of cervical cancer. J. Cell Biochem. Suppl. 23:1995;55-60.
30. Kimchi A., Wang X.F., Weinberg R.A., Cheifetz S., Massague J. Absence of TGF-beta receptors and growth inhibitory responses in retinoblastoma cells. Science. 240:1988;196-199.
31. Hahn S.A., Schutte M., Hoque A.T.et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 271:1996;350-353.
32. Markowitz S.D., Roberts A.B. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 7:1996;93-102.
33. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
34. Giaccia A.J., Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12:1998;2973-2983.
35. Agarwal M.L., Agarwal A., Taylor W.R., Stark G.R. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA. 92:1995;8493-8497.
36. Stewart N., Hicks G.G., Paraskevas F., Mowat M. Evidence for a second cell cycle block at G2/M by p53. Oncogene. 10:1995;109-115.
37. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
38. Yin C., Knudson C.M., Korsmeyer S.J., Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 385:1997;637-640.
39. Field S.J., Tsai F.Y., Kuo F.et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 85:1996;549-561.
40. Yamasaki L., Jacks T., Bronson R., Goillot E., Harlow E., Dyson N.J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 85:1996;537-548.
41. Johnson D.G., Schwarz J.K., Cress W.D., Nevins J.R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 365:1993;349-352.
42. Qin X.Q., Livingston D.M., Kaelin Jr W.G., Adams P.D. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. USA. 91:1994;10918-10922.
43. Dynlacht B.D., Moberg K., Lees J.A., Harlow E., Zhu L. Specific regulation of E2F family members by cyclin-dependent kinases. Mol. Cell Biol. 17:1997;3867-3875.
44. Krek W., Xu G., Livingston D.M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 83:1995;1149-1158.
45. Xu M., Sheppard K.A., Peng C.Y., Yee A.S., Piwnica-Worms H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. Cell Biol. 14:1994;8420-8431.
46. Dynlacht B.D., Flores O., Lees J.A., Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev. 8:1994;1772-1786.
47. Zindy F., Eischen C.M., Randle D.H.et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:1998;2424-2433.
48. ARF links pRB and p53. Nature. 395:1998;124-125.
49. Tsai K.Y., Hu Y., MacLeod K.F., Crowley D., Yamasaki L., Jacks T. Mutaion of E2F-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol. Cell. 2:1998;293-304.
50. Pan H.C.Y., Dyson N.J., Harlow E., Yamasaki L., Van Dyke T. Key roles for E2F1 in signaling p53-dependent apoptosis and in cell division within developing tumors. Mol. Cell. 2:1998;283-292.
51. De Gregori J., Leone G., Miron A., Jakoi L., Nevins J.R. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. USA. 94:1997;7245-7250.
52. Leone G., De Gregori J., Yan Z.et al. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev. 12:1998;2120-2130.
53. Hsieh J.K., Fredersdorf S., Kouzarides T., Martin K., Lu X. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev. 11:1997;1840-1852.
54. Berry D.E., Lu Y., Schmidt B.et al. Retinoblastoma protein inhibits IFN-gamma induced apoptosis. Oncogene. 12:1996;1809-1819.
55. Fan G., Ma X., Kren B.T., Steer C.J. The retinoblastoma gene product inhibits TGF-beta1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells. Oncogene. 12:1996;1909-1919.
56. Haupt Y., Rowan S., Oren M. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene. 10:1995;1563-1571.
57. Haas-Kogan D.A., Kogan S.C., Levi D.et al. Inhibition of apoptosis by the retinoblastoma gene product. EMBO J. 14:1995;461-472.
58. Dou Q.P., An B., Antoku K., Johnson D.E. Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease family. J. Cell Biochem. 64:1997;586-594.
59. Tan X., Martin S.J., Green D.R., Wang J.Y.J. Degradation of retinoblastoma protein in tumor necrosis factor- and CD95-induced cell death. J. Biol. Chem. 272:1997;9613-9616.
60. Fattman C.L., An B., Dou Q.P. Characterization of interior cleavage of retinoblastoma protein in apoptosis. J. Cell Biochem. 67:1997;399-408.
61. Janicke R.U., Walker P.A., Lin X.Y., Porter A.G. Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J. 15:1996;6969-6978.
62. An B., Jin J.R., Lin P., Dou Q.P. Failure to activate interleukin 1beta-converting enzyme-like proteases and to cleave retinoblastoma protein in drug-resistant cells. FEBS Lett. 399:1996;158-162.
63. Cdc2 kinase. Mol. Cell. 2:1998;581-591.
64. Newbold R.F., Overell R.W. Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature. 304:1983;648-651.
65. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:1997;593-602.
66. Askew D.S., Ashmun R.A., Simmons B.C., Cleveland J.L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 6:1991;1915-1922.
67. Evan G.I., Wyllie A.H., Gilbert C.S.et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119-128.
68. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000.
69. Pomerantz J., Schreiber-Agus N., Liegeois N.J.et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723.
70. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:1998;725-734.
71. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA. 95:1998;8292-8297.
72. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
73. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:1997;25-27.
74. INK4A//CDKN2A tumor suppressor and its relatives. Biochem Biophys Acta Rev Cancer 1998, in press.
75. Lane D.P. Cancer. p53, guardian of the genome. Nature. 358:1992;15-16.
76. Linette G.P., Li Y., Roth K., Korsmeyer S.J. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc. Natl. Acad. Sci. USA. 93:1996;9545-9552.
77. O'Reilly L.A., Huang D.C., Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 15:1996;6979-6990.
78. Brady H.J., Gil-Gomez G., Kirberg J., Berns A.J. Bax alpha perturbs T cell development and affects cell cycle entry of T cells. EMBO J. 15:1996;6991-7001.
79. Graeber T.G., Osmanian C., Jacks T.et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
80. Livingstone L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70:1992;923-935.
81. Yin Y., Tainsky M.A., Bischoff F.Z., Strong L.C., Wahl G.M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 70:1992;937-948.
82. Bodnar A.G., Ouellette M., Frolkis M.et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352.
83. Vaziri H., Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8:1998;279-282.
84. Fields S., Song O. A novel genetic system to detect protein-protein interactions. Nature. 340:1989;245-246.
85. Augenlicht L.H., Taylor J., Anderson L., Lipkin M. Patterns of gene expression that characterize the colonic mucosa in patients at genetic risk for colonic cancer. Proc. Natl. Acad. Sci. USA. 88:1991;3286-3289.